IBZM tool: A fully automated expert system for the evaluation of IBZM SPECT studies

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 9, 2006, Pages 1073-1083

  Buchert, Ralph ^a   Berding, Georg ^b   Wilke, Florian ^a   Martin, Brigitte ^a   Von Borczyskowski, Daniel ^a   Mester, Janos ^a   Brenner, Winfried ^a   Clausen, Malte ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

123I iodobenzamide; Dopamine receptors; IBZM; Parkinsonian syndromes; Single photon emission computed tomography

Indexed keywords

IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; AGED; ARTICLE; AUTOANALYZER; AUTOMATION; BRAIN TOMOGRAPHY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS SOFTWARE; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DOCUMENTATION; DRUG UPTAKE; EVALUATION; FEMALE; HUMAN; MALE; MEASUREMENT ERROR; MOTION ANALYSIS SYSTEM; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; STEREOTAXIC SURGERY; VOLUME OF INTEREST;

ADULT; AGED; BRAIN; CASE-CONTROL STUDIES; EXPERT SYSTEMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SOFTWARE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33747044944     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0067-9     Document Type: Article

References (49)

1. 125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci 1988;42:2097-2104
2. 123I in humans. Eur J Nucl Med 1990;16:813-816
3. Kung HF, Alavi A, Chang W, Kung MP, Keyes JW Jr, Velchik MG et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573-579
4. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707
5. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556-561
6. 123I-IBZM single photon emission computed tomography. Arch Neurol 1993;50:513-516
7. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677-692
8. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202
9. Brucke T, Wober C, Podreka I, Wober-Bingol C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 1995;15:513-518
10. 123I] iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-49
11. 123I-iodobenzamide SPECT study. J Nucl Med 2005;46:1028-1033
12. Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220-228
13. 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992;32:743-748
14. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996;93:9235-9240
15. Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:674-677
16. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997;17:162-174
17. 123I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000;157:127-129
18. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993;34:2076-2084
19. Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, et al. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun 1997;18:811-822
20. 2 receptor ligands. Eur J Nucl Med Mol Imaging 2002;29:BP23-BP29
21. 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000;41:220-227
22. Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun 2005;26:39-43
23. 123I-IBZM using the rotating gamma camera. Nucl Med Commun 1991;12:687-697
24. Gutzki J, Martin B, Wilke F, Buchert R, Mester J, Clausen M. Time dependence of striatum to background ratio in 123-I-IBZM SPET. Eur J Nucl Med Mol Imaging 2003;30:S157
25. Buchert R, Mester J, Bohuslavizki KH, Clausen M. Performance characteristics of a new low-cost four-headed small-field-of-view gamma camera dedicated for brain imaging. J Nucl Med 2001;42:886
26. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210
27. Larisch R, Meyer W, Klimke A, Kehren F, Vosberg H, Muller-Gartner HW. Left-right asymmetry of striatal dopamine D2 receptors. Nucl Med Commun 1998;19:781-787
28. Duarte P, Hustinx R, Couturier O, Smith RJ, Alavi A. Hottest pixel analysis: useful value or statistical artifact? J Nucl Med 1999;40:292P
29. Kuikka JT, Bergstrom KA, Ahonen A, Hiltunen J, Haukka J, Lansimies E, et al. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360
30. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia. Nuklearmedizin 1994;33:194-199
31. Weissenborn K, Berding G, Kostler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis 2000;15:173-178
32. Muller-Vahl KR, Berding G, Kolbe H, Meyer GJ, Hundeshagen H, Dengler R, et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurol Scand 2000;101:165-171
33. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39
34. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98
35. Armitage P, Berry G. Statistical methods in medical research, 3rd edn. Malden, USA: Blackwell Science Ltd; 1998
36. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310
37. Acton PD, Pilowsky LS, Suckling J, Brammer MJ, Ell PJ. Registration of dynamic dopamine D2 receptor images using principal component analysis. Eur J Nucl Med 1997;24:1405-1412
38. Nikkinen P, Liewendahl K, Savolainen S, Launes J. Validation of quantitative brain dopamine D2 receptor imaging with a conventional single-head SPET camera. Eur J Nucl Med 1993;20:680-683
39. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545-553
40. Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage 2003;19:601-612
41. Van Laere K, Koole M, D'Asseler Y, Versijpt J, Audenaert K, Dumont F, et al. Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med 2001;42:361-375
42. Laulumaa V, Kuikka JT, Soininen H, Bergstrom K, Lansimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123. Arch Neurol 1993;50:509-512
43. Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study. Neuroimage 1999;10:397-407
44. Jenkins TW, Truex RC. Dissection of the human brain as a method for its fractionation by weight. Anat Rec 1963;147:359-366
45. Acton PD, Pilowsky LS, Kung HF, Ell PJ. Automatic segmentation of dynamic neuroreceptor single-photon emission tomography images using fuzzy clustering. Eur J Nucl Med 1999;26:581-590
46. Plotkin M, Amthauer H, Quill S, Marzinzik F, Klostermann F, Klaffke S, et al. Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. J Neural Transm 2005;112:1355-1361
47. Parellada E, Lomena F, Catafau AM, Bernardo M, Font M, Fernandez-Egea E, et al. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Res 2004;130:79-84
48. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998;13:438-445
49. Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G. Down-regulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. Eur Neurol 2002;47:113-117